Companies
Outlook Therapeutics Faces a Decisive July Between the FDA and Capital Dilution
Outlook Therapeutics faces a crucial July: shareholder meeting for capital increase and FDA decision on its flagship drug. Shares rise 144% in 2026.
FDA
Latest FDA news
2 articles
Companies
Outlook Therapeutics: FDA to Decide on Eye Drug Lytenava on July 29
Outlook Therapeutics faces a pivotal July: shareholders vote on capital increase on the 16th and FDA decides on Lytenava on the 29th.